Search
for
Sort by
Research 121–150 of 1000+
- Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- iNOS inhibits hair regeneration in obese diabetic (ob/ob) mice
- Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha Inhibitors
- Adverse Side Effects of 5α‐Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Leydig Cell Hyperplasia and Adenomas in Mice Treated with Finasteride, a 5α-Reductase Inhibitor: A Possible Mechanism
- 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
- Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
- Purified Vitexin Compound 1 Inhibits UVA-Induced Cellular Senescence in Human Dermal Fibroblasts by Binding Mitogen-Activated Protein Kinase 1
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Maternal androgen excess inhibits fetal cardiomyocytes proliferation through RB-mediated cell cycle arrest and induces cardiac hypertrophy in adulthood
- In silico prediction of prostaglandin D2 synthase inhibitors from herbal constituents for the treatment of hair loss
- [4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs
- Fibroblast growth factor 5-short (FGF5s) inhibits the activity of FGF5 in primary and secondary hair follicle dermal papilla cells of cashmere goats
- Ageratum Conyzoides L. Extract Inhibits 5α-Reductase Gene Expression and Prostaglandin D2 Release in Human Hair Dermal Papilla Cells and Improves Symptoms of Hair Loss in Otherwise Healthy Males and Females in an Open Label Pilot Study
- Exposure to gamma-rays at the telogen phase of the hair cycle inhibits hair follicle regeneration at the anagen phase in mice
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond